Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons

Revista Iberoamericana de Micologia

Volumn 22, Issue 2, 2005, Pages 83-92

  Sánchez Vargas, Luis Octavio ^a,b   Ortiz López, Natalia Guadalupe ^a   Villar, María ^a   Moragues, Maria Dolores ^a   Aguirre, José Manuel ^a   Cashat Cruz, Miguel ^c   Lopez Ribot, Jose Luis ^d   Gaitán Cepeda, Luis Alberto ^b   Quindós, Guillerimo ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Antifungal; Candida; HIV; Mexico; Oral

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CHILD; CONTROLLED STUDY; FUNGAL COLONIZATION; FUNGAL STRAIN; FUNGUS ISOLATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MALE; MOUTH CAVITY; PREVALENCE; SEROTYPING; T LYMPHOCYTE; THRUSH; VIRUS LOAD;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; SACCHAROMYCES CEREVISIAE;

EID: 23144439444     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(05)70014-0     Document Type: Article

References (57)

1. Barchiesi F, Arzeni D, Del Prete MS, Sinicco A, Falconi Di Francesco L, Pasticci MB, Lamura L, Nuzzo MM, Burzacchini F, Coppola S, Chiodo F, Scalise G. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidiasis. J Antimicrob Chemother 1998; 41: 541-548.
2. Barchiesi F, Maracci M, Radi B, Arzeni D, Baldassarri I, Giacometti A, Scalise G. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2002; 50: 999-1002.
3. Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol 1993; 9: 455-456.
4. Barturen B, Bikandi J, San Millán R, Moragues MD, Regúlez P, Quindós G, Pontón J. Variability in expression of antigens responsible for serotype specificity in Candida albicans. Microbiology 1995; 141: 1535-1543.
5. Barturen B, Quindós G, San Millán R, Lipperheide V, Tellaetxe M, Elósegui R, Ribacoba L, Contreras I, Aguirre JM, Pontón J. Distribución de los serotipos de Candida albicans en aislamientos clínicos de personas inmunocompetentes e inmunosuprimidas. Rev Iberoam Micol 1996; 13: 10-13.
6. Bikandi J, San Millán R, Moragues MD, Cebas G, Coleman DC, Quindos G, Pontón J. Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes. J Clin Microbiol 1998; 36: 2428-2433
7. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002; 44: 169-174.
8. Brawner DL, Anderson GL, Yuen KY. Serotype prevalence of Candida albicans from blood culture isolates. J Clin Microbiol 1992; 30: 149-153.
9. Brawner DL, Cutler JE. Oral Candida albicans isolates from non-hospitalized normal carriers, immunocompetent hospitalized patients and immunocompromised patients with or without acquired immunodeficiency syndrome. J Clin Microbiol 1989; 27: 1335-1341.
10. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 448-453.
11. Ceballos A, Aguirre JM, Echebarria MA, Ceballos L. Prevalencia y distribución de las candidiasis orales en pacientes con SIDA establecido. Med Oral 1996; 1: 6-10.
12. Ceballos García L, Quindós-Andrés G, Ceballos Salobreña A. Prevalence of oral manifestations associated with human immunodeficiency virus infection in a homosexual population. Med Oral 1999; 4: 470-484.
13. Ceballos Salobreña A, Gaitán Cepeda LA, Orihuela Cañada F, Barrionuevo Olea D, Ceballos García L, Quindós G. Resistencia in vitro a los antifúngicos en Candida albicans de pacientes infectados por el VIH con y sin candidiasis oral. Rev Iberoam Micol 1999; 16: 194-197.
14. Ceballos Salobreña A, Quindós Andrés G, Ceballos García L. The influence of different risk behaviors in the appearance of oral candidiasis in AIDS patients. Med Oral 2000; 5: 71-80.
15. Ceballos-Salobreña A, Antúnez-Gálvez JM, Aguirre-Urízar JM, Bagán JV, Ceballos-García L. Oral lesions associated to human immunodeficiency virus infection in a series of 510 patients. Med Oral 1998; 3: 199-206.
16. Ceballos-Salobreña A, Gaitán-Cepeda L, Ceballos- García L, Samaranayake LP. The effect of antiretroviral therapy on the prevalence of HIV-associated oral candidiasis in a Spanish cohort. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97: 345-350.
17. CONASIDA. Panorama Epidemiologico del VIH/SIDA e ITS en México. Consejo Nacional para la prevención y control del VIH/SIDA, Secretaría de Salud, México. Dirección General de Epidemiología. Available at: http://www.salud.gob.mx/conasida.
18. Contreras I, Pontón J, Quindós G. Prevalence of Candida parapsilosis in the oral cavities of infants in Spain. Clin Infect Dis 1994; 18: 480-481.
19. Davey KG, Holmes AD, Johnson EM, Szekely A, Warnock DW. Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. J Clin Microbiol 1998; 36: 926-930.
20. De Bernardis F, Chiani P, Ciccozzi M, Pellegrini G, Ceddia T, D'Offizzi G, Quinti I, Sullivan PA, Cassone A. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun 1996; 64: 466-471.
21. Diekema DJ, Pfaller MA, Messer SA, Houston A, Hollis RJ, Doern GV, Jones RN. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America. Antimicrob Agents Chemother 1999; 43: 2236-2239.
22. Diz Dios P, Ocampo A, Miralles C, Otero I, Iglesias I, Rayo N. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87: 437-441.
23. Diz Dios P, Ocampo A, Otero I, Iglesias I, Martinez C. Changes in oropharyngeal colonization and infection by Candida albicans in Human immunodeficiency virus-infected patients. J Infect Dis 2001; 183: 355-356.
24. Drouhet E, Mercier-Soucy L, Montplaisir S. [Sensitivity and resistance of pathogenic yeasts to 5-fluoropyrimidines. I. Relation between the phenotypes of resistance to 5-fluorocytosine, the serotype of Candida albicans and the ecology of various species of Candida of human origin]. Ann Microbiol (Paris) 1975; 126B: 25-39.
25. Gaitán-Cepeda L, Cashat-Cruz M, Morales-Aguirre JJ, Sánchez-Vargas L, Aquino-Garcáa S, Fragoso-Rios R, Cuairan-Ruidiaz V, Ávila-Figueroa C. Prevalence of oral lesions in Mexican children with perinatally acquired HIV: association with immunologic status, viral load, and gender. AIDS Patient Care STDS 2002; 16: 151-156.
26. Gottfredsson M, Cox GM, Indridason OS, De Almeida GMD, Heald AE, Perfect JR. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 1999; 180: 534-537.
27. Hannula J, Dogan B, Slots J, Okte E, Asikainen S. Subgingival strains of Candida albicans in relation to geographical origin and occurrence of periodontal pathogenic bacteria. Oral Microbiol Immunol 2001; 16: 113-118.
28. Hannula J, Saarela M, Alaluusua S, Slots J, Asikainen S. Phenotypic and genotypic characterization of oral yeasts from Finland and the United States. Oral Microbiol Immunol 1997; 12: 358-365.
29. Hasenclever HF, Mitchell WO. Antigenic studies of Candida. IV. The relationship of the antigenic groups of Candida albicans to their isolation from various clinical specimens. Sabouraudia 1963; 2: 201-204.
30. Klein RS, Arnsten JH, Sobel JD. Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181: 812-813.
31. Lehner T. Oral candidiasis. Dent Pract 1967; 17: 209-216
32. Martin MV, Lamb DJ. Frequency of Candida albicans serotypes in patients with denture-induced stomatitis and in normal denture wearers. J Clin Pathol 1982; 35: 888-891.
33. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of orppharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 1291-1294.
34. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25: 843-846.
35. McMullan-Vogel CG, Jude HD, Ollert MW, Vogel CW. Serotype distribution and secretory acid proteinase activity of Candida albicans isolated from the oral mucosa of patients with denture stomatitis. Oral Microbiol Immunol 1999; 14: 183-189.
36. Morace G, Tamburrini E, Manzara S, Antinori A, Maiuro G, Dettori G. Epidemiological and clinical aspects of mycoses in patients with AIDS-related pathologies. Eur J Epidemiol 1990; 6: 398-403.
37. Mosca CO, Moragues MD, Llovo J, Al Mosaid A, Coleman DC, Ponton J. Casein agar: a useful medium for differentiating Candida dubliniensis from Candida albicans. J Clin Microbiol 2003; 41: 1259-1262.
38. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-Second Edition. NCCLS document M27-A2. Wayne, NCCLS, 2002.
39. Odds FC. Candida and candidiasis. 2nd ed. London: Baillière Tindall, 1988.
40. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrobial Chemother 1993; 31: 463-471.
41. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
42. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada and South America for the SENTRY program. J Clin Microbiol 1998; 36: 1886-1889.
43. Pinjon E, Sullivan D, Salkin I, Shanley D, Coleman D. Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J Clin Microbiol 1998; 36: 2093-2095.
44. Quindós G, Ruesga MT, Mart́in-Mazuelos E, Salesa R, Alonso-Vargas R, Carrillo-Muñoz AJ, Brena S, San Millán R, Ponton J. In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Rev Iberoam Micol 2004; 21: 21: 63-69.
45. Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, Gonzalez-Ramirez I, Ponce-de-Leon S. The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients: A 12-year study in a referral center in Mexico. Medicine (Baltimore) 2003; 82: 39-50.
46. Samaranayake LP, Yaacob HB. Classification of oral candidiasis. In: Samaranayake LP, MacFarlane TW (Eds.) Oral candidiasis. London, Butterworth, 1990; 124-132.
47. Sánchez Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Gaitán LA, Quindós G. Oral Candida isolates colonizing or infecting Mexican HIV-infected and healthy persons. J Clin Microbiol 2005; 43: in press.
48. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-85.
49. Stallybrass FC. The incidence of the serological groups of Candida albicans in Southern England. J Hyg (Lond.) 1964; 62: 395-399.
50. Stiller RL, Bennett JE, Scholer HJ, Wall M, Polak A, Stevens DA. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother 1982; 22: 482-487.
51. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol 2002; 40: 341-350.
52. Williams DW, Lewis MAO. Isolation and identification of Candida from the oral cavity. Oral Dis 2000; 6: 3-11.
53. Willinger B, Apfalter P, Hirschl AM, Makristathis A, Rotter M, Seibold M. Susceptibility testing of Candida species: comparison of NCCLS microdilution method with Fungitest®. Diagn Microbiol Infect Dis 2000; 38: 11-15.
54. Willinger B, Engelmann E, Hofmann H, Metzger S, Apfalter R Hirschl AM, Makristathis A, Rotter M, Raddatz B, Seibold M. Multicenter comparison of Fungitest for susceptibility testing of Candida species. Diagn Microbiol Infect Dis 2002; 44: 253-257.
55. Witthuhn F, Toubas D, Beguinot I, Aubert D, Rouger C, Remy G, Pinon JM. Evaluation of the Fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility. J Clin Microbiol 1999; 3: 864-866.
56. Wroblewska MM, Swoboda-Kopec E, Rokosz A, Krawczyk E, Marchel H, Luczak M. Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles. Int J Antimicrob Agents 2002; 20: 472-475.
57. Xu J, Mitchell TG. Geographical differences in human oral yeast flora. Clin Infect Dis 2003; 36: 221-224.